AMAG Pharmaceuticals Inc. Daily Stock Analysis

Daily Stock Analysis, AMAG, AMAG Pharmaceuticals Inc, priceseries

AMAG Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
13.75
Close
13.75
High
13.76
Low
13.75
Previous Close
13.73
Daily Price Gain
0.02
YTD High
77.73
YTD High Date
Jul 17, 2015
YTD Low
2.25
YTD Low Date
Jan 10, 2001
YTD Price Change
10.38
YTD Gain
307.41%
52 Week High
77.73
52 Week High Date
Jul 17, 2015
52 Week Low
2.25
52 Week Low Date
Jan 10, 2001
52 Week Price Change
10.38
52 Week Gain
307.41%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Sep 6. 2017
18.20
Sep 18. 2017
19.39
8 Trading Days
6.54%
Link
LONG
Feb 13. 2018
13.70
Mar 13. 2018
19.78
19 Trading Days
44.37%
Link
LONG
May 7. 2018
20.70
May 23. 2018
23.04
12 Trading Days
11.28%
Link
LONG
Jul 9. 2018
20.65
Jul 23. 2018
21.69
10 Trading Days
5.04%
Link
LONG
Jul 31. 2018
22.05
Aug 16. 2018
24.60
12 Trading Days
11.57%
Link
LONG
Jun 26. 2019
9.23
Jul 8. 2019
9.78
7 Trading Days
6.01%
Link
LONG
Aug 8. 2019
9.29
Aug 20. 2019
10.92
8 Trading Days
17.51%
Link
LONG
Aug 29. 2019
10.71
Sep 13. 2019
11.91
10 Trading Days
11.20%
Link
LONG
Nov 20. 2019
9.83
Dec 30. 2019
12.15
26 Trading Days
23.55%
Link
LONG
Jul 14. 2020
7.70
Aug 21. 2020
10.59
28 Trading Days
37.51%
Link
Company Information
Stock Symbol
AMAG
Exchange
NasdaqGS
Company URL
http://www.amagpharma.com
Company Phone
6174983300
CEO
William K. Heiden
Headquarters
Massachusetts
Business Address
1100 WINTER STREET, WALTHAM, MA 02451
Sector
Equity
Industry Category
Drugs
Industry Group
Diagnostic Substances
CIK
0000792977
About

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that focuses on the development and commercialization of a therapeutic iron compound to treat iron deficiency anemia. It focuses on the development and commercialization of Feraheme injection for intravenous or IV, use to treat iron deficiency anemia or IDA. The company engages in manufacture, development and commercialization of products derived from its proprietary technology for use in treating human diseases. The company was founded on 9th, November 1981 and is headquartered in Waltham, MA.

Description

AMAG Pharmaceuticals, Inc., a biopharmaceutical company, manufactures, develops, and commercializes therapeutics for women's health, anemia management, and cancer supportive care in the United States. It markets Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients with chronic kidney disease; and MuGard Mucoadhesive Oral Wound Rinse for the management of oral mucocitis/stomatiits and various types of oral wounds. The company also offers Cord Blood Registry services that are related to the collection, processing, and storage of umbilical cord blood and cord tissue units for pregnant women and their families. In addition, it has a option agreement with Velo to acquire the rights to digoxin immune fab, a polyclonal antibody in clinical development for the treatment of severe preeclampsia in pregnant women. The company sells Feraheme to authorized wholesalers and specialty distributors. It has a license agreement with Palatin Technologies, Inc. to research, develop, and commercialize Rekynda, an investigational product designed to be an on-demand treatment for hypoactive sexual desire disorder in pre-menopausal women, as well as with Endoceutics, Inc. to develop and commercialize pharmaceutical products with dehydroepiandrosterone; and development and license agreement with Antares Pharma, Inc. to develop, use, sell, and offer for sale and import and export the Makena auto-injector. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading